Skip to main content
    U

    UroGen Pharma Ltd (URGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.87
    +1.77 (+6.30%)

    Market Cap: $1.28B

    Last updated: Nov 17, 2026 at 6:00 PM ET

    UroGen Pharma Ltd (URGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    UroGen Pharma (URGN) has a market cap of $1.28B and an enterprise value of $1.39B. Revenue grew 159.29% over the last 12 months from the 12 months before. It kept -26.27% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 8.28% above the market cap, as debt exceeds cash.

    Market Cap$1.28B
    Enterprise Value$1.39B
    Latest price (Nov 17, 2026)$29.87

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.35% in the quarter ended Sep 30, 2026 and grew 3.96% a year over 2 years.

    Shares Outstanding50.56M
    Shares Change (YoY)+5.20%
    Shares Change (QoQ)+0.35%
    Share Count Growth (2Y CAGR)+3.96%

    Valuation Ratios

    The price to sales ratio is 6.0x. Its year-end P/S ranged from 3.1x to 346.5x from 2017 to 2025.

    P/S Ratio6.0x
    Forward P/S4.0x

    Price Statistics

    The stock is up 25.72% over 52 weeks and trades 17.94% below its 50-day average.

    Beta (1Y)1.17
    52-Week Change+25.72%
    1-Month Change-12.53%
    3-Month Change-40.60%
    6-Month Change+5.70%
    5-Year Change+90.23%
    Total Return (1Y)+25.72%
    Total Return (3Y CAGR)+33.83%
    Total Return (5Y CAGR)+19.01%
    Return vs SPY (1Y)+15.28%
    Max Drawdown (1Y)-50.79%
    Max Drawdown (3Y)-79.67%
    Sharpe Ratio (1Y)0.38
    Correlation with SPY (1Y)0.26
    50-Day Average$36.40
    200-Day Average$31.78
    52-Week Range$16.50 to $50.81
    RSI (14 Days)44.5
    Average Volume (20 Days)1.49M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.40x current liabilities.

    Current Ratio3.40x
    Quick Ratio3.06x
    Interest Coverage-2.78x

    Returns and Efficiency

    Return on invested capital is -73.72% over the last 12 months.

    Return on Assets (ROA)-24.18%
    Return on Invested Capital (ROIC)-73.72%
    Return on Capital Employed (ROCE)-24.86%
    ROA (5Y Average)-70.36%
    Asset Turnover1.10x
    Inventory Turnover0.86x
    Receivables Turnover2.43x
    Cash Conversion Cycle-164 days

    Scores

    URGN has an Altman Z-Score of -1.75, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.75
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $250.25M over the last 12 months.

    Revenue$250.25M
    Revenue Growth (YoY)+159.29%
    Gross Profit$228.75M
    Operating Income-$30.94M
    Pretax Income-$64.15M
    Net Income-$65.75M
    EBIT-$49.19M
    Reported EPS (TTM)-$1.31

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$85.56M
    Total Debt$191.94M
    Net Debt$106.37M
    Net Debt Per Share$2.10
    Working Capital$177.87M
    Shareholder Equity-$125.22M
    Total Assets$271.87M
    Total Liabilities$397.09M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $203.00K of capital spending, operating cash flow left -$132.05M of free cash flow.

    Operating Cash Flow-$131.85M
    Capital Expenditures$203.00K
    Free Cash Flow-$132.05M
    FCF Per Share-$2.70
    Depreciation and Amortization$5.16M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -12.36%.

    Gross Margin91.41%
    Operating Margin-12.36%
    Pretax Margin-25.64%
    Net Margin-26.27%
    EBIT Margin-19.66%
    FCF Margin-52.77%
    Gross Margin (5Y Average)88.98%

    Growth

    Revenue grew 19.49% a year over 3 years.

    Revenue Growth (3Y CAGR)+19.49%
    Revenue Growth (5Y CAGR)+56.22%

    Revenue and profit by year

    Dividends and Yields

    URGN does not pay a dividend. Its free cash flow yield is -8.74%.

    FCF Yield-8.74%
    Buyback Yield-2.11%
    Shareholder Yield-2.11%

    Peer Position

    Against 10 similar companies, URGN has the 6th highest P/S.

    P/S Ratio6.0x vs 4.7x median
    ROIC-73.72% vs -7.40% median
    Revenue Growth (Trailing 4 Quarters, YoY)+159.29% vs +24.54% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 120.71% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+120.71%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About URGN

    What is URGN's market cap?

    UroGen Pharma has a market cap of $1.28B. Its enterprise value, which adds debt and subtracts cash, is $1.39B.

    How many shares of URGN are outstanding?

    UroGen Pharma has 50.56M shares outstanding. The count is up 5.20% from a year earlier.

    Does URGN pay a dividend?

    No. UroGen Pharma does not pay a dividend.

    How much debt does URGN have?

    UroGen Pharma has $191.94M of total debt and $85.56M of cash and equivalents, a net debt position of $106.37M.